ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GBT Global Blood Therapeutics Inc

68.49
0.00 (0.00%)
After Hours
Last Updated: 20:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 68.47
Ask Price 68.50
News -
Company Name Stock Ticker Symbol Market Type
Global Blood Therapeutics Inc GBT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 68.49 20:00:00
Open Price Low Price High Price Close Price Prev Close
68.49 68.49
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 68.49 USD

Global Blood Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.62B - - - -13.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Global Blood Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No GBT Message Board. Create One! See More Posts on GBT Message Board See More Message Board Posts

Historical GBT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Global Blood Therapeutics Description

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Your Recent History

Delayed Upgrade Clock